Akero Therapeutics COO reports option exercises and stock gift

Rhea-AI Filing Summary

Akero Therapeutics, Inc. Chief Operating Officer Form 4 activity reports stock option exercises and a charitable gift of common stock. On 11/24/2025, the reporting person exercised three stock option grants, acquiring 4,284 shares at an exercise price of $21.09, 3,527 shares at $28.35, and 4,739 shares at $21.10. After these exercises, direct holdings increased, and following the reported transactions the person directly owned 200,189 shares of Akero common stock.

On 11/26/2025, the individual reported a transaction coded as a gift, transferring 9,259 shares of common stock at a reported price of $0 to a donor advised fund. In addition to direct ownership, the filing shows indirect ownership of 20,000 Akero shares in each of three irrevocable trusts for the benefit of the reporting person’s children, for a total of 60,000 indirectly held shares. The reporting person disclaims beneficial ownership of the trust-held securities, and notes that the stock options exercised are vested and currently exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Jonathan

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BOULEVARD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		M		4,284	A	$21.09	201,182	D
Common Stock	11/24/2025		M		3,527	A	$28.35	204,709	D
Common Stock	11/24/2025		M		4,739	A	$21.1	209,448	D
Common Stock	11/26/2025		G(2)		9,259	D	$0	200,189	D
Common Stock								20,000	I	By EA Irrevocable Trust(1)
Common Stock								20,000	I	By CM Irrevocable Trust(1)
Common Stock								20,000	I	By JL Irrevocable Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.09	11/24/2025		M			4,284	(3)	12/12/2029	Common Stock	4,284	$0	0	D
Stock Option (Right to Buy)	$28.35	11/24/2025		M			3,527	(3)	12/07/2030	Common Stock	3,527	$0	0	D
Stock Option (Right to Buy)	$21.1	11/24/2025		M			4,739	(3)	12/07/2031	Common Stock	4,739	$0	0	D

Explanation of Responses:

1. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund.

3. The options are vested and currently exercisable.

	/s/ Jonathan Young	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.